References
- Larder B, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243: 1731–4.
- Hirsch MS. HIV drug resistance: a chink in the armour. NEJM 2002; 347: 438–9.
- Kellam P, Larder B. Recombinat virus assay: a rapid phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1994; 38: 23–30.
- Federal Register. Medical Devices Classification. 1997, Vol 62, 62243–60
- Richman DD. Principles of HIV resistance testing and overview of assay performance characteristics. Antiviral Therapy 2000; 5: 2731.
- Hertogs K, Zolopa AR, Bloor S, et al. A blinded comparative analysis of two genotype service laboratories: full sequence analysis of HIV-1 protease and reverse transcriptase [abstract 87]. Antiviral Therapy 1999; 4(Suppl.1): 59.
- Qari SH, Respess R, Weinstock H, Beltrami EM, Hertogs K, Larder BA, et al. Comparative analysis of 2 commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1. J Clin Microbiol 2002; 40: 31–5.
- D’Aquila RT. Nucleosides and Foscarnet:Clinical Aspects. In: Richman DD, ed. Antiviral Drug Resistance. Wiley; 1996.
- Anon. Antiretroviral drug resistance testing in adult HIV-1infection. JAMA 1998; 279: 1984–91.
- Anon. Antiretroviral drug resistance testing in adult HIV-1 infection. JAMA 2000; 283: 2417–26.
- Durant J, Clevembergh P, Halfon P, et al. Drug–resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet 1999; 353: 2195–9.
- Cohen CJ, Hunt S, Sension M, et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002; 16: 579–88.
- Weinstein MC, Goldie SJ, Losina E, et al. Use of genotypic resistance to guide HIV therapy: clinical impact and costeffectiveness. Ann Intern Med 2001; 134: 440–50.
- Genotypic and phenotypic resistance testing. P1 Perspective 1998; 25: 9–10.
- Hale P Phenotyping breakthrough: a remarkable new tool for quantifying HIV drug resistance, Searchlight 1997; 9–16.
- Anon. Reports from the HIV Drug Resistance Collaborative Group Meeting. Antiviral Therapy 2000; 5: 23–83.
- The Euroguidelines Group for HIV resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS 2001; 15: 309–20.
- Schimidt B, Korn K, Moschik B, et al. Comparison of different algorithms for the interpretation of genotypic data for protease inhibitors [abstract 79]. Antiviral Therapy 2000; 5(Suppl. 3): 60.
- Robert I, Fontaine E, Lambert C, et al. Inter-person variability in interpreting sequencing results of HIV-1 resistance testing [abstract 70]. Antiviral Therapy 2000; 5(Suppl. 3): 54.
- Larder B, Kemp SD, Hetrtogs K. Quantitative prediction of HIV phenotypic drug resistance from genotypes: the virtual phenotype [abstract 63]. Antiviral Therapy 2000; 5(Suppl. 3): 50.
- Beerenwinkel N, Schmidt B, Walter H, et al. Diversity and complexity of HIV-1 drug resistance: a bioinformatic approach to predicting phenotype from genotype. PNAS 2002; 99: 8271–6.
- De Gruttola V, Dix L, D’Aquila R, et al. The relationship between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Therapy 2000; 5: 41–8.